The U.S. Food and Drug Administration (FDA) has regulated tobacco products since 2009. Thoughtful, science- and evidence-based federal regulation will help address societal concerns about tobacco products and promote and protect public health.

To achieve Altria’s Vision, we invest in the foundational science needed to demonstrate that smoke-free tobacco products are less harmful than cigarettes and to support the product applications we submit to the U.S. Food & Drug Administration (FDA).

The success of tobacco harm reduction in the United States requires a regulatory framework that allows manufacturers to provide adults who smoke with a portfolio of smoke-free products authorized by the Food and Drug Administration (FDA).

Altria Group, Inc. (Altria) (NYSE: MO) announces today that the U.S. Food and Drug Administration (FDA) issued marketing orders for NJOY ACE Pod Menthol 2.4%, NJOY ACE Pod Menthol 5%, NJOY DAILY Menthol 4.5%, and NJOY DAILY Extra Menthol 6%.

CTP sends letters to industry to provide updates, help industry understand FDA regulations and policies, and request information, per Section 904 (b) of the Federal Food, Drug, and Cosmetic...

Science is at the core of Altria’s approach to Tobacco Harm Reduction. Our investment in research and technology supports our work on smoke-free platforms and the science needed for product applications submitted to the Food and Drug Administration (FDA).

Altria Client Services today announced that the Food and Drug Administration (FDA) has accepted and filed for substantive review premarket tobacco product applications for 35 on! products manufactured by Helix Innovations LLC, an Altria joint venture responsible for the global on! nicotine pouch product portfolio.

Today, Altria Group, Inc. (Altria) announces the submission of Premarket Tobacco Product Applications (PMTAs) to the U.S. Food and Drug Administration (FDA) for its innovative on! PLUS oral nicotine pouch products.

Altria Client Services LLC (“ALCS”), on behalf of John Middleton Co. (“JMC”),1 submits these comments to the U.S. Food and Drug Administration (“FDA” or “the Agency”) in response to the proposed rule that would prohibit characterizing flavors in cigars, “Tobacco Product

Jun 10, 2020 · Altria Client Services announced that the Food and Drug Administration (FDA) has accepted and filed for substantive review premarket tobacco product applications for 35 on!® products manufactured by Helix Innovations LLC, an Altria joint venture responsible for the global on!® nicotine pouch product portfolio.